Optibrium introduces StarDrop 5.4 to target novel, safe and efficacious drugs

Optibrium, a developer of software for drug discovery, today announced the release of version 5.4 of its StarDrop software platform.
Register for free to listen to this article
Listen with Speechify
0:00
1:00
 
Optibrium Ltd. 

Optibrium, a developer of software for drug discovery, todayannounced the release of version 5.4 of its StarDrop software platform. Itoffers enhanced features to guide the design of novel, safe and efficaciousdrugs by providing access to world-leading technologies for toxicity predictionand bioisosteric transformations. These new optional modules further extendStarDrop's capabilities to intuitively target high-quality compounds in drugdiscovery, reducing the time and cost to deliver drug candidates with animproved chance of success.
 


Optibrium Ltd.

www.optibrium.com

info@optibrium.com 

+44 1223 815900
 

Related Topics

Published In

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Surface rendering of two interacting proteins (green and peach) bound together by a small molecule ligand at their interface, illustrating a protein-ligand binding event.
Learn how molecular dynamics, AI-aided design, and structural insights combine to reshape how therapeutic proteins are created, validated, and optimized.
Stem cells are shown as clear, purple, and blue spheres against a dark blue and black background.
Human-relevant, ready-to-use stem cell models are reshaping drug discovery, toxicity testing, and personalized medicine.
Characterizing lipid nanoparticles for RNA therapeutic development
Integrated multiomics and advanced nanoparticle analytics are improving how researchers perform RNA delivery, increasing therapeutic success.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue